MA41134B1 - Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales - Google Patents
Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections viralesInfo
- Publication number
- MA41134B1 MA41134B1 MA41134A MA41134A MA41134B1 MA 41134 B1 MA41134 B1 MA 41134B1 MA 41134 A MA41134 A MA 41134A MA 41134 A MA41134 A MA 41134A MA 41134 B1 MA41134 B1 MA 41134B1
- Authority
- MA
- Morocco
- Prior art keywords
- prophylaxis
- treatment
- viral infections
- thiazolo
- pyrimidin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- YDWRPBIUDIYAOX-UHFFFAOYSA-N 5-amino-3,4-dihydro-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound O=C1NC(N)=NC2=C1SC(=O)N2 YDWRPBIUDIYAOX-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014093224 | 2014-12-08 | ||
| CN2015086987 | 2015-08-14 | ||
| PCT/EP2015/078439 WO2016091698A1 (en) | 2014-12-08 | 2015-12-03 | 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41134A MA41134A (fr) | 2017-10-18 |
| MA41134B1 true MA41134B1 (fr) | 2021-03-31 |
Family
ID=54771116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41134A MA41134B1 (fr) | 2014-12-08 | 2015-12-03 | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US9441008B2 (OSRAM) |
| EP (1) | EP3230298B1 (OSRAM) |
| JP (1) | JP6817217B2 (OSRAM) |
| KR (2) | KR102557560B1 (OSRAM) |
| CN (2) | CN107445980B (OSRAM) |
| AU (1) | AU2015359692B2 (OSRAM) |
| BR (1) | BR112017011941B1 (OSRAM) |
| CA (1) | CA2963717C (OSRAM) |
| CL (1) | CL2017001426A1 (OSRAM) |
| CR (1) | CR20170237A (OSRAM) |
| DK (1) | DK3230298T3 (OSRAM) |
| EA (1) | EA038744B1 (OSRAM) |
| ES (1) | ES2864223T3 (OSRAM) |
| HR (1) | HRP20210454T1 (OSRAM) |
| HU (1) | HUE053704T2 (OSRAM) |
| IL (1) | IL251285B (OSRAM) |
| LT (1) | LT3230298T (OSRAM) |
| MA (1) | MA41134B1 (OSRAM) |
| MX (1) | MX379474B (OSRAM) |
| MY (1) | MY194002A (OSRAM) |
| PE (1) | PE20170679A1 (OSRAM) |
| PH (1) | PH12017501061A1 (OSRAM) |
| PL (1) | PL3230298T3 (OSRAM) |
| PT (1) | PT3230298T (OSRAM) |
| RS (1) | RS61612B1 (OSRAM) |
| SG (1) | SG11201704512PA (OSRAM) |
| SI (1) | SI3230298T1 (OSRAM) |
| TW (1) | TWI733656B (OSRAM) |
| UA (1) | UA124184C2 (OSRAM) |
| WO (1) | WO2016091698A1 (OSRAM) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102557560B1 (ko) * | 2014-12-08 | 2023-07-20 | 에프. 호프만-라 로슈 아게 | 바이러스 감염의 치료 또는 예방을 위한 3-치환된 5-아미노-6H-티아졸로[4,5-d]피리미딘-2,7-다이온 화합물 |
| SI3270915T1 (sl) | 2015-03-16 | 2020-07-31 | F. Hoffmann-La Roche Ag | Kombinirano zdravljenje z agonistom TLR7 in zaviralcem sestavljanja kapside HBV |
| EP4001283A1 (en) * | 2015-05-12 | 2022-05-25 | F. Hoffmann-La Roche AG | Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection |
| EP3317289B1 (en) | 2015-06-30 | 2021-10-27 | F. Hoffmann-La Roche AG | Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| EP4234691A3 (en) | 2016-10-14 | 2023-10-18 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| CN110139868B (zh) * | 2017-01-06 | 2021-07-09 | 豪夫迈·罗氏有限公司 | 制备3-取代的5-氨基-6H-噻唑并[4,5-d]嘧啶-2,7-二酮化合物的方法 |
| WO2018127526A2 (en) * | 2017-01-06 | 2018-07-12 | F. Hoffmann-La Roche Ag | New solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate |
| US12012421B2 (en) | 2017-07-07 | 2024-06-18 | Hoffmann-La Roche Inc. | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate |
| US12012420B2 (en) | 2017-11-21 | 2024-06-18 | Hoffmann-La Roche, Inc. | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate |
| JP2021506827A (ja) | 2017-12-15 | 2021-02-22 | シルバーバック セラピューティックス インコーポレイテッド | 肝炎の治療用の抗体コンストラクト−薬物コンジュゲート |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| WO2019165374A1 (en) | 2018-02-26 | 2019-08-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| WO2019226977A1 (en) * | 2018-05-25 | 2019-11-28 | Primmune Therapeutics, Inc. | Tlr7 agonists |
| AU2019300324A1 (en) | 2018-07-13 | 2021-01-21 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating RTEL1 expression |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| US12318403B2 (en) | 2019-03-07 | 2025-06-03 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′-cyclic dinucleotides and prodrugs thereof |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| EP3986474A1 (en) | 2019-06-19 | 2022-04-27 | Silverback Therapeutics, Inc. | Anti-mesothelin antibodies and immunoconjugates thereof |
| US11339159B2 (en) * | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
| IL293293A (en) | 2019-11-26 | 2022-07-01 | Primmune Therapeutics Inc | tlr7 agonists |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| IL294161A (en) | 2019-12-24 | 2022-08-01 | Hoffmann La Roche | Method of treating virus infection using a tlr7 agonist |
| EP4081217A1 (en) | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
| WO2021130266A1 (en) | 2019-12-24 | 2021-07-01 | F. Hoffmann-La Roche Ag | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |
| WO2021177679A1 (ko) | 2020-03-02 | 2021-09-10 | 성균관대학교산학협력단 | 병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법 |
| CN115605493A (zh) | 2020-03-20 | 2023-01-13 | 吉利德科学公司（Us） | 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法 |
| EP4194010A4 (en) | 2020-08-04 | 2025-03-26 | Progeneer Inc. | Conjugate of a functional drug and a toll-like receptor 7 or 8 agonist with a temporarily inactivated drug site, and use thereof |
| JP7690221B2 (ja) | 2020-08-04 | 2025-06-10 | プロジェニア インコーポレイテッド | 動力学的に作用するアジュバントアンサンブル |
| CN116322751A (zh) | 2020-08-04 | 2023-06-23 | 蛋白科技先锋 | 包含能够动力学控制的佐剂的mRNA疫苗 |
| CA3190794A1 (en) | 2020-08-05 | 2022-02-10 | Soren Ottosen | Oligonucleotide treatment of hepatitis b patients |
| CA3215049A1 (en) | 2021-04-10 | 2022-10-13 | Baiteng ZHAO | Folr1 binding agents, conjugates thereof and methods of using the same |
| JP7742892B2 (ja) | 2021-04-23 | 2025-09-22 | ジェンマブ エー／エス | 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法 |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| AU2022384619A1 (en) | 2021-11-11 | 2024-04-11 | F. Hoffmann-La Roche Ag | Pharmaceutical combinations for treatment of hbv |
| WO2025032082A1 (en) * | 2023-08-08 | 2025-02-13 | F. Hoffmann-La Roche Ag | Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds |
| TW202535954A (zh) | 2023-09-26 | 2025-09-16 | 丹麥商珍美寶股份有限公司 | Ｐｔｋ７結合劑、其共軛物及使用彼等之方法 |
| US20250296992A1 (en) | 2024-01-10 | 2025-09-25 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| WO2025181219A1 (en) | 2024-02-29 | 2025-09-04 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5476659A (en) | 1982-11-09 | 1995-12-19 | The Scripps Research Institute | Cancerous B cell treatment using substituted nucleoside derivatives |
| US5166141A (en) | 1983-11-01 | 1992-11-24 | Scripps Clinic And Research Foundation | Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals |
| US5041426A (en) * | 1987-12-21 | 1991-08-20 | Brigham Young University | Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides |
| EP1072607A3 (en) | 1996-10-16 | 2001-09-12 | ICN Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses therof |
| SI20024A (sl) | 1996-10-16 | 2000-02-29 | Icn Pharmaceuticals, Inc. | Purinovi L-nukleozidi, analogi in uporaba od teh |
| WO2005016235A2 (en) | 2003-04-14 | 2005-02-24 | The Regents Of The University Of California | Combined use of impdh inhibitors with toll-like receptor agonists |
| WO2005025583A2 (en) | 2003-09-05 | 2005-03-24 | Anadys Pharmaceuticals, Inc. | Tlr7 ligands for the treatment of hepatitis c |
| CN101212968B (zh) * | 2004-12-17 | 2011-11-16 | 安那迪斯药品股份有限公司 | 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药 |
| ES2459368T3 (es) * | 2004-12-17 | 2014-05-09 | Anadys Pharmaceuticals, Inc. | Compuestos de 3H-oxazolo y 3H-tiazolo[4,5-d]pirimidin-2-ona 3,5-disustituidos y 3,5,7-trisustituidos y profármacos de los mismos |
| ATE474842T1 (de) | 2005-11-21 | 2010-08-15 | Anadys Pharmaceuticals Inc | Neues verfahren zur herstellung von 5-amino-3h- thiazoloä4,5-düpyrimidin-2-on |
| CL2007001427A1 (es) | 2006-05-22 | 2008-05-16 | Novartis Ag | Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po |
| ATE496924T1 (de) * | 2006-06-22 | 2011-02-15 | Anadys Pharmaceuticals Inc | Prodrugs von 5-amino-3-(3'-deoxy-beta-d- ribofuranosyl)-thiazolä4,5-düpyrimidin-2,7-dion |
| BRPI0714831A2 (pt) | 2006-07-18 | 2013-04-02 | Anadys Pharmaceuticals Inc | composto, composiÇço farmacÊutica e mÉtodos de modulaÇço de atividades imuno da citoquina em paciente, de tratamento de infecÇço de vÍrus c da hepatite em paciente e de desordem relacionada com proliferaÇço em mamÍfero necessitado do mesmo |
| BRPI0717741A2 (pt) | 2006-10-17 | 2014-04-08 | Anadys Pharmaceuticals Inc | Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença |
| US20110166092A1 (en) * | 2007-08-20 | 2011-07-07 | Anadys Pharmaceuticals, Inc. | Dosing methods for treating disease |
| KR102557560B1 (ko) * | 2014-12-08 | 2023-07-20 | 에프. 호프만-라 로슈 아게 | 바이러스 감염의 치료 또는 예방을 위한 3-치환된 5-아미노-6H-티아졸로[4,5-d]피리미딘-2,7-다이온 화합물 |
| SI3270915T1 (sl) | 2015-03-16 | 2020-07-31 | F. Hoffmann-La Roche Ag | Kombinirano zdravljenje z agonistom TLR7 in zaviralcem sestavljanja kapside HBV |
| EP4001283A1 (en) | 2015-05-12 | 2022-05-25 | F. Hoffmann-La Roche AG | Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection |
| EP3317289B1 (en) | 2015-06-30 | 2021-10-27 | F. Hoffmann-La Roche AG | Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection |
-
2015
- 2015-12-03 KR KR1020177015128A patent/KR102557560B1/ko active Active
- 2015-12-03 AU AU2015359692A patent/AU2015359692B2/en active Active
- 2015-12-03 PT PT158041285T patent/PT3230298T/pt unknown
- 2015-12-03 MA MA41134A patent/MA41134B1/fr unknown
- 2015-12-03 HR HRP20210454TT patent/HRP20210454T1/hr unknown
- 2015-12-03 PE PE2017000551A patent/PE20170679A1/es unknown
- 2015-12-03 ES ES15804128T patent/ES2864223T3/es active Active
- 2015-12-03 DK DK15804128.5T patent/DK3230298T3/da active
- 2015-12-03 EA EA201791011A patent/EA038744B1/ru unknown
- 2015-12-03 BR BR112017011941-2A patent/BR112017011941B1/pt active IP Right Grant
- 2015-12-03 MY MYPI2017702051A patent/MY194002A/en unknown
- 2015-12-03 EP EP15804128.5A patent/EP3230298B1/en active Active
- 2015-12-03 RS RS20210297A patent/RS61612B1/sr unknown
- 2015-12-03 KR KR1020237024143A patent/KR20230113824A/ko not_active Ceased
- 2015-12-03 PL PL15804128T patent/PL3230298T3/pl unknown
- 2015-12-03 UA UAA201706823A patent/UA124184C2/uk unknown
- 2015-12-03 CA CA2963717A patent/CA2963717C/en active Active
- 2015-12-03 CR CR20170237A patent/CR20170237A/es unknown
- 2015-12-03 JP JP2017548325A patent/JP6817217B2/ja active Active
- 2015-12-03 LT LTEP15804128.5T patent/LT3230298T/lt unknown
- 2015-12-03 SI SI201531553T patent/SI3230298T1/sl unknown
- 2015-12-03 WO PCT/EP2015/078439 patent/WO2016091698A1/en not_active Ceased
- 2015-12-03 US US14/958,619 patent/US9441008B2/en active Active
- 2015-12-03 CN CN201710845723.5A patent/CN107445980B/zh active Active
- 2015-12-03 CN CN201580018026.1A patent/CN106164079B/zh active Active
- 2015-12-03 HU HUE15804128A patent/HUE053704T2/hu unknown
- 2015-12-03 SG SG11201704512PA patent/SG11201704512PA/en unknown
- 2015-12-03 MX MX2017007044A patent/MX379474B/es unknown
- 2015-12-07 TW TW104140978A patent/TWI733656B/zh active
-
2016
- 2016-07-11 US US15/207,338 patent/US10040815B2/en active Active
-
2017
- 2017-03-20 IL IL251285A patent/IL251285B/en unknown
- 2017-06-05 CL CL2017001426A patent/CL2017001426A1/es unknown
- 2017-06-07 PH PH12017501061A patent/PH12017501061A1/en unknown
-
2018
- 2018-07-02 US US16/025,170 patent/US10618929B2/en active Active
-
2020
- 2020-04-13 US US16/847,552 patent/US11180525B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41134B1 (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| MA46038A (fr) | Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale | |
| MA41338A (fr) | Composés de pyrazine pour le traitement de maladies infectieuses | |
| MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
| EA201991399A1 (ru) | Аминотриазолопиридиновые соединения и их применение в лечении рака | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| MA38323A1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| EP4374858A3 (en) | Benzimidazolone derived inhibitors of bcl6 | |
| MA37942B1 (fr) | Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b | |
| MA37712A2 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
| WO2019035864A8 (en) | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS | |
| MA38315B1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| EP4371562A3 (en) | 2-quinolone derived inhibitors of bcl6 | |
| MA33745B1 (fr) | Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes | |
| MX380516B (es) | Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico | |
| CR20200584A (es) | Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| MA38009A1 (fr) | Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| PH12022551012A1 (en) | 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease | |
| MA42972B1 (fr) | Nouveaux composés sulfonimidoylpurinone et dérivés pour le traitement et la prophylaxie d'infection virale | |
| MA38591A1 (fr) | Héteroaryldihydropyrimidines pontées en position 6 pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b | |
| FR3028762B1 (fr) | Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine |